Genmab (GMAB) boosts share capital via DKK 37.9m employee warrant exercise
Rhea-AI Filing Summary
Genmab A/S reports a small capital increase driven by the exercise of employee warrants. Share capital will rise by 24,592 shares, corresponding to approximately 0.04% of the company’s share capital. The warrants were exercised for cash at three strike prices: 4,702 shares at DKK 1,334.50, 2,069 shares at DKK 1,362.50, and 17,821 shares at DKK 1,615.00, generating total proceeds of about DKK 37.9 million for Genmab. The new ordinary shares carry no special rights, are freely transferable, and will participate in dividends and other shareholder rights from subscription. After the increase, total share capital will be DKK 62,377,844, divided into 62,377,844 shares of nominal DKK 1 each. The new shares will be listed on Nasdaq Copenhagen following registration with the Danish Business Authority.
Positive
- None.
Negative
- None.
Filing Explained
As a Form 6-K interim report, this filing places the employee-warrant capital increase at an expected near-term finalization stage; the added shares increase the share count and reduce existing holders’ percentage ownership, while listing awaits registration with the Danish Business Authority.
Key Figures
New shares issued: 24,592 shares
Proceeds from warrant exercise: DKK 37.9 million
Portion of share capital: 0.04%
+5 more
8 metrics
New shares issued
24,592 shares
Share capital increase from employee warrant exercises
Proceeds from warrant exercise
DKK 37.9 million
Aggregate cash proceeds from exercised employee warrants
Portion of share capital
0.04%
New shares as a percentage of Genmab’s share capital
Post-increase share capital (nominal)
DKK 62,377,844
Total nominal share capital after the capital increase
Post-increase shares outstanding
62,377,844 shares
Number of shares of nominal DKK 1 each after the increase
Warrants exercised at DKK 1,334.50
4,702 shares at DKK 1,334.50
One of three exercise price tranches for employee warrants
Warrants exercised at DKK 1,362.50
2,069 shares at DKK 1,362.50
Second exercise price tranche for employee warrants
Warrants exercised at DKK 1,615.00
17,821 shares at DKK 1,615.00
Largest exercise price tranche for employee warrants
Key Terms
preemption rights, employee warrants, nominal value, Danish Capital Markets Act, +2 more
6 terms
preemption rights regulatory
"The increase is effected without any preemption rights for the existing shareholders"
Preemption rights give existing shareholders the first chance to buy newly issued shares so they can keep the same fraction of ownership. Think of it like getting first dibs on extra slices of pizza so your portion of the pie doesn’t shrink. For investors this matters because it protects voting power and value per share by preventing unexpected loss of ownership when a company issues more stock.
employee warrants financial
"Capital Increase in Genmab as a Result of Employee Warrant Exercise"
nominal value financial
"shares of a nominal value of DKK 1 each, corresponding to 62,377,844 votes"
Nominal value is the stated or face amount assigned to a financial instrument — for shares it’s the par value printed on the stock certificate, and for money or returns it can mean the number not adjusted for inflation. Think of it like a price tag on an item versus its buying power: the tag tells you the label, but not how much you can actually buy. Investors care because nominal values affect accounting, legal capital, dividend calculations and comparisons over time when inflation may distort real worth.
Danish Capital Markets Act regulatory
"Pursuant to section 32 of the Danish Capital Markets Act No. 464"
A national law that sets the rules for trading, reporting and oversight of securities and financial markets in Denmark; think of it as the official rulebook that governs how companies, investors and intermediaries must behave when raising capital or trading shares. It matters to investors because it mandates information disclosure, market transparency and conduct standards that reduce fraud, make prices more reliable and protect shareholder rights, helping investors judge risks and make informed decisions.
bispecific antibodies medical
"advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies"
Engineered proteins that can attach to two different biological targets at once, like a two-headed key that fits two locks simultaneously; in medicine they often link immune cells to diseased cells or block two disease pathways at the same time. Investors care because this dual-action design can improve effectiveness or open new treatment options, but it also raises development complexity, manufacturing cost and regulatory risk, affecting a biotech company’s value and partnerships.
antibody–drug conjugates (ADCs) medical
"antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What capital increase did Genmab (GMAB) announce in August 2026?
Genmab announced a capital increase of 24,592 shares, equal to about 0.04% of its share capital, resulting from the exercise of employee warrants and leading to new ordinary shares with full shareholder rights.
How much cash will Genmab (GMAB) receive from the employee warrant exercise?
Genmab will receive approximately DKK 37.9 million in cash proceeds from the exercise of employee warrants, based on three subscription prices ranging from DKK 1,334.50 to DKK 1,615.00 per share.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE MONTH OF AUGUST 2026
COMMISSION FILE NUMBER 001-38976
Genmab A/S
(Exact name of Registrant as specified in its charter)
(Exact name of Registrant as specified in its charter)
Carl Jacobsens Vej 30
2500 Valby
Denmark
+45 70 20 27 28
(Address of principal executive offices)
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F Form 40-F
This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273, 333-284876 and 333-293505) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
| Exhibit | Description of Exhibit | ||||
| 99.1 | Company Announcement Dated August 11, 2026: Capital Increase in Genmab as a Result of Employee Warrant Exercise | ||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| GENMAB A/S | ||||||||
| BY: | /s/ Anthony Pagano | |||||||
| Name: Anthony Pagano | ||||||||
| Title: Executive Vice President & Chief Financial Officer | ||||||||
DATE: AUGUST 11, 2026
Exhibit 99.1
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement
COPENHAGEN, Denmark; August 11, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 24,592 shares as a consequence of the exercise of employee warrants.
The increase is effected without any preemption rights for the existing shareholders of the Company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:
4,702 shares at DKK 1,334.50,
2,069 shares at DKK 1,362.50, and
2,069 shares at DKK 1,362.50, and
17,821 shares at DKK 1,615.00.
Proceeds to the Company are approximately DKK 37.9 million. The increase corresponds to approximately 0.04% of the Company's share capital.
The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. The capital increase is expected to be finalized shortly.
Pursuant to section 32 of the Danish Capital Markets Act No. 464 of May 1, 2026, it is hereby announced, that the total nominal value of Genmab A/S' share capital after the capital increase is DKK 62,377,844 which is made up of 62,377,844 shares of a nominal value of DKK 1 each, corresponding to 62,377,844 votes.
About Genmab
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.
Contact:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
| Genmab A/S Carl Jacobsens Vej 30 2500 Valby, Denmark | Tel: +45 7020 2728 www.genmab.com | Company Announcement no. 35 Page 1/2 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 | ||||||
Capital Increase in Genmab as a Result of Employee Warrant Exercise
The Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in the Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®.
| Genmab A/S Carl Jacobsens Vej 30 2500 Valby, Denmark | Tel: +45 7020 2728 www.genmab.com | Company Announcement no. 35 Page 2/2 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 | ||||||